A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

This phase 3 study (GTI1503; EudraCT #: 2015–003,290-15; clinicaltrials.gov identifier NCT02806986) was a multicenter, single-arm, open-label study conducted in 8 countries at 22 participating centers in the United Kingdom, Hungary, Germany, Czech Republic, Spain, France, Poland, and Australia. Screened and/or enrolled subjects had PI with impaired antibody production, including combined immunodeficiency syndromes (e.g., Hyper-IgM syndrome).

The study involved 2 phases: a screening/previous regimen phase and an IGSC 20% treatment phase. During the screening/previous regimen phase, subjects continued to take their existing IVIG or SCIG treatment (previous regimen) and underwent measurement of 2 IgG trough levels. If all eligibility criteria were met, subjects completed the screening/previous regimen phase and entered the treatment phase. In the treatment phase, subjects self-administered IGSC 20% at home (caregivers administered IGSC 20% to young children). They had been trained and observed at 3 successive clinic visits to assure adequate understanding and technical expertise. Following baseline assessments, subjects entering the study on IVIG commenced treatment with SC IGSC 20% using a 1:1 dose adjustment factor (DAF). They continued to receive SC IGSC 20% as a weekly dose for 52 weeks and completed a final follow-up visit at week 53.

The study protocol was approved by Institutional Review Boards/Ethics Committees/Research Ethics Boards at all participating institutions and by regulatory authorities in all countries in which it was conducted. All subjects provided written informed consent before any study-related procedures were undertaken, and the clinical study was conducted in full conformance with applicable local laws and regulations, the Declaration of Helsinki, and the international standards of Good Clinical Practice.

Eligible subjects included children, adolescent, and adult males and females between the ages of 2 and 75 years (inclusive) at screening, with a documented and confirmed pre-existing diagnosis of PI with features of hypogammaglobulinemia requiring IgG replacement therapy, including but not limited to humoral-based immunodeficiency syndromes and combined immunodeficiency syndromes without lymphocytopenia [27]. Subjects could not have had an SBI within the last 3 months prior to screening and up to the time of the baseline visit, as well as during the screening/previous regimen phase and prior to the first study treatment. Subjects had to be on a stable regimen (dose and dosage) of IVIG or SCIG for at least 3 consecutive months. Those receiving IVIG prior to study participation must have received a dosage of at least 200 mg/kg per infusion. Subjects also had to have documentation (within the previous 6 months) of an IgG trough level of ≥ 500 mg/dL on the current IgG replacement therapy regimen, and they had to have screening/pre-baseline trough IgG levels of at least 500 mg/dL.

Subjects were ineligible to participate in the study if they had clinical evidence of any significant acute or chronic disease that may have interfered with successful completion of the trial or placed the subject at undue medical risk. They were also excluded if they had a known serious adverse reaction to immunoglobulin or any severe anaphylactic reaction to blood or any blood-derived product; a history of blistering skin disease, clinically significant thrombocytopenia, bleeding disorder, diffuse rash, recurrent skin infections, or other disorders where SC therapy would be contraindicated; isolated IgG subclass deficiency, isolated specific antibody deficiency disorder, or transient hypogammaglobulinemia of infancy; or a known selective IgA deficiency with or without antibodies to IgA. Females of childbearing potential who were pregnant, had a positive pregnancy test at screening (serum) or baseline (urine) (human chorionic gonadotropin-based assay), were breastfeeding, or unwilling to practice a highly effective method of contraception throughout the study were excluded. Subjects with significant proteinuria (dipstick proteinuria ≥ 3 + , known urinary protein loss > 1 g/24 h, or nephrotic syndrome), a history of acute renal failure, severe renal impairment (blood urea nitrogen or creatinine more than 2.5 times the upper limit of normal), and/or on dialysis were ineligible, as were subjects whose aspartate aminotransferase or alanine aminotransferase levels exceeded 2.5 times the upper limit of normal and those with hemoglobin < 9 g/dL at screening. Subjects were also excluded if they had a history of (1 year before screening or 2 lifetime episodes) or current hepatitis B virus; hepatitis C virus; deep venous thrombosis; or thromboembolism; were receiving anti-coagulation therapy that would make SC administration inadvisable; had a known hyperviscosity syndrome; had an acquired medical condition that was known to cause secondary immune deficiency; were positive for human immunodeficiency virus; had uncontrolled arterial hypertension; were receiving immunosuppressants, immunomodulators, or long-term systemic corticosteroids (i.e., daily dose > 1 mg of prednisone equivalent/kg/day for > 30 days); were known to abuse psychoactive substances or prescription drugs. Subjects who had participated in another clinical trial within 30 days prior to screening or received any investigational blood product (except other IgG products) within the previous 3 months, as well as those who were unwilling to comply with any aspect of the protocol for the duration of the study, were considered ineligible.

The study treatment was Grifols IGSC 20%, a sterile liquid formulation containing 20% human immune globulin formulated in 0.16–0.26 M glycine and 10–40 parts per million polysorbate 80 at pH 4.1–4.8. IGSC 20% is manufactured using the same process as for Gamunex 10%, except that ultrafiltration is added to achieve the 20% IgG concentration.

Eligible subjects, including those on IVIG, received IGSC 20% at the same weekly equivalent dose as their previous IgG replacement regimen. Beginning 1 week after the last IVIG dose or at the time when their next commercial SCIG dose was due, weekly IGSC 20% was administered for 52 weeks at a minimum dose of IGSC 20% of 100 mg/kg/week.

The primary efficacy endpoint was the number and frequency of SBIs, as defined by the EMA guideline and FDA guidance for analyzing annualized SBI rate in primary efficacy analysis [26, 28]. Secondary efficacy endpoints included the rate of infection of any kind (serious and non-serious); antibiotic treatment (oral, parenteral, oral plus parenteral, prophylactic, and therapeutic); hospitalizations due to infection; days lost from work/school/daily activities due to infections and related treatment; and mean total IgG trough levels during steady state. Additional parameters included average trough concentration of IgG subclasses (IgG1, IgG2, IgG3, and IgG4) and concentration of antibody levels to S. pneumoniae, H. influenzae, C. tetani (tetanus), and measles.

The study included a subset of adults (planned n ~ 20) for PK profiling, with serial samples collected immediately before and after SC#17 infusion at steady state over a 7-day period. Parameters included area under the concentration versus time curve from time 0 to 7 days (AUC_0-7 days), the observed maximum total IgG concentration (C_max), and the observed time to reach the first observed maximum total IgG concentration (t_max) and were determined by standard non-compartmental methods using Phoenix WinNonlin (Certara USA, Inc., Princeton, NJ, USA).

Safety was evaluated monthly for clinical findings (AE and infusion site reaction assessments, physical examination, and vital signs) and laboratory testing. To confirm the appropriate use of study treatment throughout the study, the self-administration of IGSC 20% was observed at scheduled clinic visits.

The efficacy-evaluable and safety populations included subjects who received any amount of IGSC 20%. The IgG population included subjects who received IGSC 20% and had sufficient trough IgG concentration data to allow the calculation of steady-state mean trough IgG in the IGSC 20% phase. The PK population included subjects in the adult PK subset who received IGSC 20% and had sufficient serial IgG concentration vs. time data to allow the calculation of PK parameters.

Descriptive statistics were calculated as appropriate for the type of endpoints (continuous/quantitative or categorical/qualitative). Geometric mean and 90% confidence interval (CI) were additionally calculated for PK parameters (except t_max). For infection-related efficacy endpoints, the rate per person per year was calculated as the total number of events or days divided by the total duration of exposure (in years) over all subjects.

Secondary and other infection-related efficacy endpoints were analyzed with the same methods as in the primary efficacy analysis. For these endpoints, the 2-sided 95% CIs (equivalent to a 2-sided alpha level of 0.05) were derived from the generalized linear model procedure for Poisson regression.

Mean trough total IgG concentration for the IGSC 20% treatment phase was calculated as the average of all steady-state trough concentrations measured during the IGSC 20% treatment phase at the following visits: week 17, 18, 20, 24, 28, 32, 36, 40, 44, 48, 52, and 53. Comparison was made to the mean trough total IgG concentration for the previous IgG regimen (either IVIG or other SCIG products), calculated as the average of 2 trough concentrations collected during the previous regimen phase.

Sample size was determined based on the primary endpoint. Assuming that the true rate of the SBIs was 0.25 per person per year, 40 subjects treated for 1 year with IGSC 20% would provide at least 90% power to reject the null hypothesis of an SBI rate greater than or equal to 1.0 per person per year, using a 1-sided test at the 0.01 level. In order to assure a total of 40 PI subjects, including 20 adult and 20 pediatric evaluable subjects, enrollment of approximately 60 subjects was planned.

Sixty-one subjects were recruited and participated in GTI1503 from 29 June 2016 through 15 May 2019 at 15 study centers in North America and Europe. All 61 subjects received IGSC 20% and were included in the safety and efficacy evaluable populations. Data from 59 subjects were valid for steady-state trough IgG concentration analysis (IgG population). A total of 29 adults participated in the PK subset, and 27 were valid for the PK analysis (PK population).

The disposition of subjects is depicted in Fig. 1. Sixty-eight subjects were screened, and 61 met eligibility criteria and were suitable for participation. Of these, 55 (90.2%) completed the study and 6 (9.8%) discontinued, 4 due to treatment-emergent adverse events (TEAEs), and 2 due to subjects’ own decision.

The study population was 52.5% (32/61) adults and 47.5% (29/61) children and adolescents; the 29 non-adults were aged 2–5 years (17.2% [5/29]), > 5 to 12 years (48.3% [14/29]), and > 12 to 16 years (34.5% [10/29]). The majority of subjects were white (93.4% [57/61]), and most were male (68.9% [42/61]). The most common types of PI were common variable immunodeficiency (CVID, 63.9% [39/61]) and X-linked agammaglobulinemia (21.3% [13/61]). Median (range) time since PI diagnosis was 5.99 (0.3–38.9) years. The previous regimen for most subjects (65.6% [40/61]) was IVIG; 34.4% (21/61) of subjects were receiving SCIG at entry. Those whose previous regimen was IVIG were more likely to be receiving treatment every 4 weeks (37.7% [23/61]) than every 3 weeks (27.9% [17/61]). Demographic and other baseline characteristics, as well as subjects’ treatment during the screening/previous regimen phase, are summarized in Table 1.

In total, 3045 IGSC 20% infusions were administered, and mean (SD) infusion compliance was 99.9 (0.59)%. The median (interquartile range [IQR]) duration of each weekly infusion was 1 (0.77–1.53) hour, the median (IQR) infusion rate was 21 (13.73–26.27) mL/h/site, and a median of 2 sites was used per infusion. Based on the IGSC 20% infusions with analyzable data (N = 3044), 261 infusions were administered to 14 subjects at infusion rates > 25 mL/h/site; the median (IQR) and mean (SD) infusion rates in this subgroup were 37.5 (33.83–44.97) and 39.4 (8.25) mL/h/site, respectively. Mean (SD) IGSC 20% dose per weekly infusion was 125.5 (28.46) mg/kg/week. Infusion parameters are summarized in Table 2.

For the primary efficacy endpoint of SBIs, only 1 subject (1.6% [1/61]), a child, experienced an infection that met the criteria for an SBI. The event of pneumonia was successfully treated on an outpatient basis with oral antibiotics, and the subject recovered within 4 days.

The total duration of IGSC 20% exposure was 58.40 subject-years. The rate of SBI was 0.017 (2-sided 98% CI: 0.006–0.036) per person per year overall. Of note, since the upper limit of the 2-sided 98% CI was statistically equivalent to the 1-sided 99% upper CL (0.036) and less than 1, the null hypothesis was rejected at a 1-sided α = 0.01 level, and the primary efficacy endpoint was met. A summary of infections and associated parameters (primary and secondary endpoint variables) is provided in Table 3.

During the IGSC 20% treatment phase, the rate of hospitalization due to infection was low (1.6% [1/61]), with only 1 event of urinary tract infection. The rate of hospitalization due to infection was 0.017 (2-sided 95% CI: 0.008–0.033) per person per year overall. The rate of infections of any kind (all severities) was 2.397 (2-sided 95% CI: 1.824–3.079) per person per year overall. Thirty-six validated infections were documented by positive radiograph, fever, culture, or positive diagnostic test for microorganisms during the treatment phase, and the rate of validated infections per person per year was 0.616 (2-sided 95% CI: 0.401–0.898).

Antibiotic usage was categorized as prophylactic or therapeutic. During the IGSC 20% treatment phase, the number of days on prophylactic antibiotics per person per year was 44.432 (2-sided 95% CI: 26.351–69.339). Overall, the number of days on therapeutic antibiotics per person per year was 8.904 (2-sided 95% CI: 5.949–12.705).

The number of days of work/school/daily activities missed per subject year due to infections and related treatment was 4.983 (2-sided 95% CI: 3.064–7.572) overall. Results for disability parameters with regard to infections and associated events were consistent across all age categories.

In the IgG population (n = 59), as shown in Table 4, the average of the steady-state mean trough concentrations of total IgG for all subjects during the previous regimen phase was 891.37 mg/dL; the IGSC 20% treatment phase results were generally comparable (947.64 mg/dL). The average mean trough ratio (treatment:previous regimen) was 1.078. A summary of the derived PK parameters (AUC, C_max, and t_max) in the PK population (n = 27) is additionally presented in Table 4.

The trough levels of IgG subclasses IgG1, IgG2, IgG3, and IgG4 reached a steady state in the IGSC 20% treatment phase by at least week 13, and the overall levels of IgG subclasses were consistent with those observed during the previous regimen phase. For example, the average IgG1 trough level was 639.0 mg/dL at week 13 of the IGSC 20% treatment phase and 561.5 mg/dL during the previous regimen phase. No preferential absorption or loss of IgG subclasses was observed, and the trough concentrations of IgG subclasses were generally consistent across the different age groups.

During IGSC 20% treatment, the mean trough antibody levels were above protective thresholds for H. Influenzae (protective ≥ 1.0 µg/mL; 0.15 µg/mL protective for invasive disease [29]) and anti-tetanus toxoid (> 0.1 IU/mL [30]). Measles mean titer values and all individual subject titers were above protective trough titers for PI patients (threshold: 0.24 IU/mL [31]). Of the 23 S. pneumoniae serotypes evaluated for antibody levels, mean antibody concentrations were generally above the protective levels for noninvasive disease (≥ 1.3 µg/mL) for most serotypes, and they exceeded the protective threshold for invasive disease (≥ 0.2 µg/mL) for all serotypes [32‐34]. Trough IgG concentrations against all pathogens analyzed were generally consistent across the different age groups.

As presented in Table 5, the TEAEs resulting in the discontinuation of 4 subjects included anxiety (not related to IGSC 20%) in a 2-year-old child, aortic valve incompetence related to congenital heart disease (not related to IGSC 20%), nephrotic syndrome (which evolved during the study and was unrelated to IGSC 20%), and subcutaneous fibroma. The subject with nephrotic syndrome was discontinued upon diagnosis. Seven subjects had 7 treatment-emergent serious AEs (SAEs), none of which were considered to be related to treatment with IGSC 20%: urinary tract infection, nephrotic syndrome, luxating patella, thrombocytopenia (subject history of immune thrombocytopenia), aortic valve incompetence requiring cardiac surgery, medical device site joint pain (orthopedic arthrodesis screw), and 1 case of outpatient pneumonia (met criteria for the primary efficacy endpoint [SBI]). The subject with the SAE of thrombocytopenia withdrew of their own volition. Local infusion site reactions reported as TEAEs occurred in 34.4% of subjects, at a rate per infusion of 0.029.

The most common TEAEs (≥ 10% incidence) during the IGSC 20% treatment phase were nasopharyngitis, infusion site erythema, infusion site pruritus, upper respiratory tract infection, cough, bronchitis, pyrexia, rhinitis, sinusitis, and headache (Table 6). Most TEAEs (97.1%) were mild or moderate in severity.